Health Secretary Kennedy Endorses and Uses Peptides Under FDA Review He Oversees

On July 23–24, 2026, an FDA advisory committee reviews seven peptides for potential compounding approval. Health Secretary Kennedy, who oversees the FDA, has endorsed the compounds, disclosed personal use with "really good effect," and decried the "FDA's war on public health." The FDA's briefing documents cite inadequate evidence of safety or effectiveness.